SAN FRANCISCO—Okupe Oluyemi, the Chief Financial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold shares of the company's Class A Common Stock valued at approximately $488,530. The transactions, executed on December 20, 2024, were part of a pre-established trading plan under Rule 10b5-1.
The sales were conducted as part of a structured trading plan adopted on May 31, 2024, allowing executives to sell a predetermined number of shares at specific times. These plans are often used to avoid potential accusations of insider trading. Trading at a P/E ratio of 57.6x, HIMS is one of 1,400+ US stocks covered by detailed Pro Research Reports, offering investors comprehensive analysis and actionable insights. Trading at a P/E ratio of 57.6x, HIMS is one of 1,400+ US stocks covered by detailed Pro Research Reports, offering investors comprehensive analysis and actionable insights.
The sales were conducted as part of a structured trading plan adopted on May 31, 2024, allowing executives to sell a predetermined number of shares at specific times. These plans are often used to avoid potential accusations of insider trading.
In other recent news, Hims & Hers Health has experienced significant developments. The U.S. Food and Drug Administration (FDA) recently announced the resolution of the tirzepatide injection shortage, a decision that could impact the market dynamics for obesity drugs. Hims & Hers Health, which had been offering compounded versions of obesity drugs, experienced a sharp decline in shares following this announcement.
In a contrasting development, Morgan Stanley (NYSE:MS) initiated coverage on Hims & Hers Health with an Overweight rating, citing a strong investment opportunity. The firm highlighted the company's impressive revenue compound annual growth rate projection of 30% from 2024 to 2026. The company's third-quarter sales also exceeded market expectations, with a year-over-year increase of 77%, surpassing $400 million.
Meanwhile, Hims & Hers Health announced a partnership with Eli Lilly (NYSE:LLY) to streamline access to FDA-approved obesity medication Zepbound. This collaboration involves integrating with LillyDirect, a self-pay pharmacy channel, further enhancing the company's service offerings. However, a similar partnership between digital health company Ro and Eli Lilly resulted in a slight drop in Hims & Hers Health shares.
Finally, in a report from Hunterbrook Media, it was suggested that the company could benefit from potential FDA leadership ties. The report indicates that the company's future could be positively impacted by President-elect Donald Trump's nominee for the FDA commissioner, Dr. Martin Makary, currently an executive at Sesame, a telehealth company that also sells compounded GLP-1 drugs online.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.